Showing results 1 to 1 of 1
| Issue Date | Title | Journal Title |
|---|---|---|
| 2025 | A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients | BRITISH JOURNAL OF CANCER |